RB1 and neoplasm: However, CDK2 would circumvent the efficacy of CDK4/6 inhibitors and was reported to render resistance to CDK4/6 inhibitors in multiple cancer types.43 Initial inhibition of Rb phosphorylation would enhance the inhibition on CDK4/6 and CDK2 in tumor cells with intact regulatory loop by accumulating p21.